Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Schiller · SciRah

Researcher profile · Semantic Scholar

G. Schiller

Share profile

G. Schiller — researcher profile on SciRah

h-index: 68
Works: 510
Citations: 20K

Most-cited papers

KTE-X19 for relapsed/refractory adult B-cell acute lymphoblastic leukemia: phase 2 results from the single-arm, multicenter ZUMA-3 study
B. Shah, A. Ghobadi, Olalekan O. Oluwole, A. Logan +27 more
2021The Lancet622 citations Open access
Semantic Scholar
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
N. Daver, A. Perl, J. Maly, M. Levis +15 more
2022Journal of Clinical Oncology159 citations Open access
Semantic Scholar
Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
A. Perl, R. Larson, N. Podoltsev, S. Strickland +17 more
2022Blood140 citations Open access
Semantic Scholar
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
J. Watts, M. Baer, Jay Yang, T. Prebet +24 more
2022The Lancet Haematology99 citations
Semantic Scholar
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
B. Shah, A. Ghobadi, Olalekan O. Oluwole, A. Logan +26 more
2022Journal of Hematology & Oncology83 citations Open access
Semantic Scholar
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Sarah M. Larson, Christopher M. Walthers, Brenda Ji, Sanaz N. Ghafouri +22 more
2022medRxiv80 citations Open access
Semantic Scholar
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
H. Erba, A. Fathi, G. Issa, J. Altman +15 more
2022Blood67 citations Open access
Semantic Scholar
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.
N. Pemmaraju, H. Kantarjian, K. Sweet, Eunice S. Wang +56 more
2022Blood48 citations Open access
Semantic Scholar
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
A. Perl, R. Larson, N. Podoltsev, S. Strickland +18 more
2022Transplantation and Cellular Therapy47 citations Open access
Semantic Scholar
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
K. Pratz, M. Cherry, J. Altman, B. Cooper +14 more
2023Journal of Clinical Oncology44 citations Open access
Semantic Scholar
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
B. Shah, R. Cassaday, Jae H. Park, R. Houot +25 more
2023Journal for ImmunoTherapy of Cancer33 citations Open access
Semantic Scholar
Fosmanogepix Therapy of Disseminated Fusarium Infection.
D. Winston, P. Young, H. Schlamm, G. Schiller
2023Clinical Infectious Diseases27 citations
Semantic Scholar
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
Sheng F. Cai, Ying Huang, J. R. Lance, H. Mao +34 more
2023Blood Advances25 citations Open access
Semantic Scholar
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial
N. Bahlis, D. Siegel, G. Schiller, C. Samaras +16 more
2022Leukemia and Lymphoma24 citations Open access
Semantic Scholar
Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience.
Sanaz N. Ghafouri, Kathleen E. Fenerty, G. Schiller, S. de Vos +4 more
2021Clinical Lymphoma, Myeloma & Leukemia24 citations Open access
Semantic Scholar
Updated Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia
M. Walters, Angela R. Smith, G. Schiller, Erica B Esrick +5 more
2021Blood24 citations
Semantic Scholar
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
Tara L. Lin, D. Rizzieri, D. Ryan, G. Schiller +9 more
2021Blood Advances24 citations Open access
Semantic Scholar
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
V. Duong, A. Ruppert, Alice S. Mims, U. Borate +33 more
2023Cancer22 citations Open access
Semantic Scholar
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
Antoine N. Saliba, S. Kaufmann, E. Stein, Prapti A. Patel +36 more
2022Blood Advances20 citations Open access
Semantic Scholar
Vaccine-associated measles in a hematopoietic cell transplant recipient: case report and comprehensive review of the literature
Sandy Y Chang, Anjali Bisht, Karolina Faysman, G. Schiller +2 more
2021Open Forum Infectious Diseases15 citations Open access
Semantic Scholar
Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).
D. White, Christine Chen, Muhamed Baljevic, S. Tuchman +15 more
202114 citations
Semantic Scholar
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
G. Schiller, B. Lipe, N. Bahlis, S. Tuchman +21 more
2023Clinical Lymphoma, Myeloma & Leukemia13 citations Open access
Semantic Scholar
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials
Chenyu Lin, Aurélie Schwarzbach, J. Sanz, P. Montesinos +29 more
2023Transplantation and Cellular Therapy13 citations Open access
Semantic Scholar
P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
A. Fathi, Eunice S. Wang, G. Issa, J. Altman +21 more
2023HemaSphere12 citations Open access
Semantic Scholar
Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components
Edward L. Snyder, A. Wheeler, M. Refaai, C. Cohn +28 more
2022Transfusion12 citations Open access
Semantic Scholar
Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma
D. White, Christine Chen, Muhamed Baljevic, S. Tuchman +27 more
2021Blood12 citations Open access
Semantic Scholar
Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
Brian D. Friend, L. Broglie, B. Logan, S. Chhabra +19 more
2022Transplantation and Cellular Therapy10 citations Open access
Semantic Scholar
Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
A. Yacoub, U. Borate, R. Rampal, H. Ali +13 more
2022Blood10 citations Open access
Semantic Scholar
Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Non-Malignant Diseases
L. Broglie, Brian D. Friend, S. Chhabra, B. Logan +18 more
2022Transplantation and Cellular Therapy9 citations Open access
Semantic Scholar
COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).
F. Ravandi, A. Kishtagari, H. Carraway, G. Schiller +5 more
2022Journal of Clinical Oncology9 citations
Semantic Scholar
AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study
J. Altman, N. Daver, J. Maly, M. Levis +12 more
20219 citations
Semantic Scholar
AML-475 Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML
H. Erba, Eunice S. Wang, G. Issa, J. Altman +27 more
2023Clinical Lymphoma, Myeloma & Leukemia8 citations
Semantic Scholar
P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
N. Boissel, P. Chevallier, K. Curran, G. Schiller +15 more
2023HemaSphere8 citations Open access
Semantic Scholar
Diminished durability of chimeric antigen receptor T‐cell efficacy with severe or prolonged postinfusion cytopenias
N. Tabbara, Jack K. Sharp, D. Gaut, Thanh Thuy Dan Pham +6 more
2022American journal of hematology/oncology8 citations
Semantic Scholar
Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
S. Abedin, M. Hamadani, S. Holtan, G. Schiller +11 more
2022Blood7 citations
Semantic Scholar
Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial
M. Patnaik, H. Ali, Eunice S. Wang, A. Yacoub +9 more
2021Blood7 citations Open access
Semantic Scholar
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
C. Gasparetto, G. Schiller, S. Tuchman, N. Callander +15 more
20217 citations
Semantic Scholar
Results of a Randomized Phase 3 Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (“SEAMLESS”)
H. Kantarjian, K. Begna, J. Altman, S. Goldberg +24 more
2021Cancer6 citations Open access
Semantic Scholar
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
G. Tremblay, P. Daniele, J. Breeze, Lingling Li +38 more
2021BMC Cancer6 citations Open access
Semantic Scholar
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories
U. Borate, Fei Yang, R. Press, A. Ruppert +27 more
2023Blood Advances5 citations Open access
Semantic Scholar
Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma
G. Schiller, S. Tuchman, N. Callander, Muhamed Baljevic +13 more
2022Blood5 citations Open access
Semantic Scholar
A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.
Omer H. Jamy, Sharif S. Khan, P. Tsirigotis, B. Tomlinson +16 more
2023Journal of Clinical Oncology4 citations
Semantic Scholar
Abstract CT026: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies
C. Dinardo, P. Montesinos, L. Benajiba, A. Triguero +38 more
2023Cancer Research4 citations
Semantic Scholar
A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage
N. Pemmaraju, Krishna Gundabolu, Jack Snyder, M. Silverman +3 more
2022Blood4 citations Open access
Semantic Scholar
Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
B. Shah, A. Ghobadi, Olalekan O. Oluwole, A. Logan +26 more
2022Blood4 citations Open access
Semantic Scholar
A slow-go prognosis for older patients with newly diagnosed AML.
G. Schiller
2021Blood4 citations
Semantic Scholar
Updated Follow-up of a Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma
Benjamin R. Puliafito, Christopher M. Walthers, Brenda Ji, Sanaz N. Ghafouri +24 more
2023Blood3 citations Open access
Semantic Scholar
Differential use of the Hematopoietic Cell Transplantation-Comorbidity Index among adult and pediatric transplant physicians
L. Broglie, Brian D. Friend, S. Chhabra, Caitrin Bupp +7 more
2022Leukemia and Lymphoma3 citations Open access
Semantic Scholar
MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study.
A. Yacoub, U. Borate, R. Rampal, H. Ali +13 more
2022Clinical Lymphoma, Myeloma & Leukemia3 citations
Semantic Scholar
A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
J. Zeidner, M. Foster, Mary Johnson, Ying Huang +28 more
2022Blood3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Baer×14
Invite
M. Baer — researcher profile on SciRah
Eunice S. Wang×11
Invite
Eunice S. Wang — researcher profile on SciRah
P. Montesinos×10
Invite
P. Montesinos — researcher profile on SciRah
J. Foran×9
Invite
J. Foran — researcher profile on SciRah

×8

Invite

J. Altman — researcher profile on SciRah

Invite

M. Arellano — researcher profile on SciRah

Invite

U. Borate — researcher profile on SciRah

Invite

A. Perl — researcher profile on SciRah

Invite

M. Litzow — researcher profile on SciRah

S. Strickland×6

Invite

S. Strickland — researcher profile on SciRah

Invite

W. Blum — researcher profile on SciRah

Alice S. Mims×6

Invite

Alice S. Mims — researcher profile on SciRah